Xtalks presents a live webinar on June 27, 2012 at 12:00pm EDT on optimizing strain design and development for efficient microbial GMP production. Dr. Joachim Klein, Group Leader, Microbial R&D, Lonza Pharmaceuticals, a leading expert on microbial research, will address the diversity of microbially derived proteins. June 22, 2012
No single strain or vector is capable of being the best expression option for all types of biopharmaceuticals. Scientists face many expression challenges including inclusion bodies, low expression levels, and product instability. Dr. Klein will discuss how to identify the best production choice for the product of interest using Lonza’s XS tool box of experimental options, including a selection of host organisms, plasmids, promoters, selection markers, signal sequences, translational initiation regions, and stabilizing elements. Assays, biolayer interferometry and capillary electrophoresis. Depending on the host organism, final strain selection is achieved within 6 to 8 weeks, starting from synthesized gene through to final production strain.
The 60-minute presentation will include case studies on common problems such as low productivity, product-related impurities, insolubility, plasmid and host instability.
This webinar is designed for fermentation and expression specialists with a focus in the areas of cell culture and strain development.
For more information or to register go to http://xtks.in/Plsluv
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx
Karen Lim (416) 977-6555 ext 227
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/6/prweb9624021.htm